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MHC molecules play a critical role in protec-
tive immunity by presenting antigenic peptide 
fragments for T cell recognition (Davis and 
Bjorkman, 1988). MHC polymorphism enhances 
immune defense across the population by 
ensuring wide variation in the T cell response 
to infecting pathogens through presentation of 
a broad array of target epitopes (Lawlor et al., 
1990; Germain and Margulies, 1993). There are 
4,000 different variants of HLA (Robinson 
et al., 2003), with polymorphism generally 
concentrated in the antigen-binding cleft, con-
trolling the size and diversity of the peptide 
repertoire presented by each HLA molecule. 
Although HLA molecules can differ from each 
other by >30 amino acids, differences of only a 
few amino acids (micropolymorphism) can have 
a major impact on immune responses (Archbold 
et al., 2009). Namely, HLA micropolymorphism 
can influence the repertoire of peptides pre-
sented on the surface of APCs (Macdonald 
et al., 2003; Burrows et al., 2007), the confor-
mation of HLA-bound peptide (Hülsmeyer 
et al., 2004; Tynan et al., 2005c), the dependence 
on chaperones for antigen loading (Zernich 
et al., 2004),  TCR recognition (Tynan 
et al., 2005a,b, 2007), and susceptibility to in-
fectious disease (Limou et al., 2009).
To engage the vast repertoire of MHC-
bound antigenic peptides, TCRs are diversified 
through the random rearrangement of V and 
J genes at the TCR locus, and V, D, and 
J genes at the TCR locus of developing 
thymic T cells. Further potential diversity is cre-
ated through untemplated addition or deletion 
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In comparison to human leukocyte antigen (HLA) polymorphism, the impact of allelic 
sequence variation within T cell receptor (TCR) loci is much less understood. Particular TCR 
loci have been associated with autoimmunity, but the molecular basis for this phenomenon 
is undefined. We examined the T cell response to an HLA-B*3501–restricted epitope 
(HPVGEADYFEY) from Epstein-Barr virus (EBV), which is frequently dominated by a 
TRBV9*01+ public TCR (TK3). However, the common allelic variant TRBV9*02, which differs 
by a single amino acid near the CDR2 loop (Gln55→His55), was never used in this  
response. The structure of the TK3 TCR, its allelic variant, and a nonnaturally occurring 
mutant (Gln55→Ala55) in complex with HLA-B*3501HPVGEADYFEY revealed that the  
Gln55→His55 polymorphism affected the charge complementarity at the TCR–peptide-MHC  
interface, resulting in reduced functional recognition of the cognate and naturally occurring 
variants of this EBV peptide. Thus, polymorphism in the TCR loci may contribute toward 
variability in immune responses and the outcome of infection.
© 2010 Gras et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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et al., 1995; Wang et al., 2002; Zhang et al., 2004; Dolan 
et al., 2006). Unrelated EBV+, HLA-B*3501+ individuals 
frequently generate CTLs against the HPVG epitope that 
express immunodominant public TCR  and  chains char-
acterized by TRAV20, TRAJ58, TRBV9, and TRBJ2-2 usage 
(Miles et al., 2006). We now show that allelic variation within 
this TRBV9 gene, which led to a Gln (TRBV9*01) to His 
(TRBV9*02) substitution at position 55 (ImMunoGeneTics 
unique numbering; Lefranc, 2003), resulted in a reduction in 
TCR binding affinity and diminished functional recognition 
of the cognate viral epitope as well as the naturally occurring 
variants of this epitope. These factors dictate the preferential 
selection of the TRBV9*01 TCR  chain gene and the exclu-
sion of TRBV9*02 in this antiviral immune response. Our data 
therefore illustrate both the sensitivity and significance of allelic 
polymorphism within the TCR loci in protective immunity.
RESULTS
Allelic variation in the TRBV9 gene
The HLA-B*3501–restricted CTL response to the 
HPVGEADYFEY epitope from EBV is characterized by 
type III–biased TCR usage (Miles et al., 2006; Turner et al., 
2006), with biases in the TRAV and TRBV genes as well as 
conserved length and sequence motifs in the CDR3 loops. 
Specifically, in multiple clones from unrelated individuals, 
this biased response was defined by closely related TCRs, 
which comprised TRAV20/TRAJ58 combined with TRBV9/
TRBJ2-2 (Miles et al., 2006). Notably, the CDR3 and 
CDR3 loops were largely germline encoded, although the 
CDR3 loops displayed a strongly biased selection of the 
random N-nucleotide–encoded Leu, whereas the CDR3 
loops were characterized by a 3–amino acid “ARS/ART/
VRT/APT” motif (Miles et al., 2006). Sequence data for 
three HPVG-specific CTL clones, isolated from three unrelated 
HLA-B*3501+ individuals, are shown in Fig. 1 a. These strong 
gene biases and selection of recurrent motifs suggested that 
they play a crucial role in determining the specificity toward 
the HLA-B*3501HPVG complex.
Polymorphism within the TRBV9 gene is common across 
various ethnic groups, with the TRBV9*01 allele occurring 
more frequently than the TRBV9*02 allele (TRBV9*01: 82, 
79, and 97%; and TRBV9*02: 18, 21, and 3% in Caucasians, 
African Americans, and Chinese, respectively; Brzezinski et al., 
2005). A single amino acid difference distinguishes these two 
alleles, with TRBV9*01 encoding a Gln and TRBV9*02 
encoding a His at position 55, which is a framework resi-
due lying directly adjacent to the CDR2 loop of the  
chain. Accordingly, we investigated the possibility that this 
TCR micropolymorphism could influence recognition of 
HLA-B*3501HPVG.
PBMCs were collected from 27 healthy, HLA-B35+, 
EBV-exposed individuals, and genomic TRBV sequencing re-
vealed that 21 donors were homozygous for the TRBV9*01 
allele, 6 donors were heterozygous for TRBV9*01 and 
TRBV9*02, and 0 donors were homozygous for the TRBV9*02 
allele. To determine if both of these alleles could be used in 
of a variable number of nucleotides at the V-(D)-J junctional 
sites, called N regions. The residual repertoire of unique 
TCRs after thymic selection is between 10 and 100 million 
in humans (Arstila et al., 1999). Despite this vast potential 
repertoire, immune responses often show strong unexplained 
biases in TCR selection, resulting in immunodominance of 
certain “public” TCRs that are widely used in individuals 
with shared MHC types (Acha-Orbea et al., 1988; Argaet 
et al., 1994; Burrows et al., 1995; Turner et al., 2006; Gras 
et al., 2008). The first and second complementarity- 
determining regions (CDRs) of the TCR are germline en-
coded within the TRAV and TRBV gene segments, whereas 
the CDR3 regions are derived from the V-(D)-J and N regions. 
From the growing number of unique TCR–peptide-MHC 
(pMHC)–I structures determined, it is apparent that a rough 
docking mode is preserved in which the V domain is posi-
tioned over the MHC-I 2 helix and the N-terminal end of 
the peptide, whereas the V domain is more often positioned 
over the MHC-I 1 helix and the C-terminal end of the 
peptide, although the precise interatomic interactions vary 
considerably between TCR–pMHC complexes (Rudolph 
et al., 2006; Godfrey et al., 2008).
As with the MHC genes, allelic sequence variation is also 
a feature of the TCR loci; however, the full extent of TCR 
polymorphism and its functional significance in influencing 
protective immunity is unknown. Nevertheless, several single 
nucleotide polymorphism (SNP) studies have revealed con-
siderable polymorphism within the TRAV and TRBV gene 
segments (Subrahmanyan et al., 2001; Mackelprang et al., 
2006). In one study, the TCR loci from 40 individuals across 
four ethnic groups were fully sequenced, and >550 SNPs 
were found, with many being situated in coding/regulatory 
regions of functional TCR genes and several causing null and 
nonfunctional mutations. On average, the coding region of 
each TCR variable gene contained two SNPs, with many 
more found in the 5, 3, and intronic sequences of these 
segments. Furthermore, a total of 51 SNPs in the TRA locus 
and 72 SNPs in the TRB locus resulted in amino acid changes 
(Subrahmanyan et al., 2001; Mackelprang et al., 2006), al-
though the structural and functional consequences of this 
sequence variation have not been investigated. Importantly, 
particular TCR loci have been associated with increased sus-
ceptibility to common immune diseases such as multiple scle-
rosis (Seboun et al., 1989; Hibberd et al., 1992; Hockertz 
et al., 1998), asthma (Moffatt et al., 1994, 1997; Cho et al., 
2001), and narcolepsy (Hallmayer et al., 2009).
In this study, we have investigated the functional and 
structural impact of natural micropolymorphism within genes 
encoding a public TCR that recognizes an 11–amino acid 
epitope, 407HPVGEADYFEY417 (referred to as HPVG), de-
rived from the EBNA-1 protein of EBV. This epitope is 
highly immunogenic in EBV-exposed healthy individuals 
expressing HLA-B*3501 (Blake et al., 1997; Lee et al., 2004; 
Tellam et al., 2004; Miles et al., 2006). Although EBV is a 
genetically stable DNA virus, sequence variation within the 
HPVG epitope has been previously described (Snudden 
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The TCR-negative human T cell line Jurkat, which had 
been engineered to stably express CD8 (Beddoe et al., 2009), 
was transduced with retroviral expression constructs encod-
ing (a) the TK3 TCR cDNA (JurkatCD8-TK3WT), (b) the 
TK3 TCR with the naturally occurring Gln→His -chain 
substitution corresponding to position 55 of TRBV9 (Jur-
katCD8-TK3Gln55His), or (c) a corresponding alanine mutant 
(JurkatCD8-TK3Gln55Ala). After cloning, these CD8+ Jurkat 
T cells expressing the wild-type and mutant TK3 TCRs were 
closely matched for levels of both CD3 and CD8 (Fig. 1 b). 
An HLA-B*3501HPVG multimer was used to assess antigen 
recognition by the TK3 TCR and its variants. The multimer 
incubation was performed at 4°C, and strong staining was 
observed for all cell lines (Fig. 1 b), confirming equivalent 
levels of TCR expression by the different transduced JurkatCD8 
cell lines. However, when the multimer staining was repeated 
using a 37°C incubation instead of 4°C and a wide range of 
multimer concentrations, minor differences in staining inten-
sity were observed between the cell lines, with two clones trans-
duced with the TK3Gln55His TCR staining with the lowest 
intensity (Fig. 1 c). This temperature sensitivity in multimer 
association suggested that the TK3Gln55His TCR may bind 
with a lower avidity to the MHC–viral peptide complex in 
comparison to the TK3WT TCR.
the response to the HPVG epitope, an HLA-B*3501HPVG 
multimer was used to sort T cells specific for the HPVG epitope 
from five of the heterozygous donors who were confirmed to 
be HLA-B*3501+. cDNA from the expressed TRBV9 gene 
products was cloned into Escherichia coli, and sequence analysis 
of at least 31 clones from each donor revealed that all were 
from the TRBV9*01 allele, indicating that TRBV9*02 was 
not used in the response to this EBV epitope (Table I). To 
confirm that these five heterozygous donors carried T cells 
expressing both TRBV9*01 and TRBV9*02 in their periph-
eral repertoire, the same cDNA sequencing procedure was 
used on unsorted PBMCs. Although T cells expressing 
TRBV9*01 were more common in the peripheral repertoire 
than those expressing TRBV9*02, these data confirmed that 
TRBV9*02-expressing T cells were available in all five donors 
for potential use in antiviral T cell immunity (Table I).
Differential functional recognition
Next, we aimed to establish why the TRBV9*01 allele was 
repeatedly selected in the response to HLA-B*3501HPVG, 
whereas the TRBV9*02 allele was not. Further TCR se-
quence analysis for the TK3 CTL clone (Fig. 1 a) confirmed 
that its  chain was encoded by the TRBV9*01 allele, and it 
was therefore studied further as a prototype of this response. 
Figure 1. TRBV9*01 is required for  
optimal recognition by a public TCR that 
dominates the response to the HPVG viral 
epitope. (a) Highly conserved V-(D)-J junc-
tional region sequences of TCR  and  
chains from CTL clones that recognize HLA-
B*3501HPVG, isolated from three unrelated 
individuals. The nucleotide sequences are 
presented, and the one-letter code designat-
ing the translated amino acid is shown above 
the first nucleotide in each codon. Colored 
areas designate nucleotides of germline ori-
gin. (b) HLA-B*3501HPVG multimer staining, 
and CD3 and CD8 cell-surface expression for 
JurkatCD8 cells transduced with the TK3WT, 
TK3Gln55His (two clones), or TK3Gln55Ala TCR. Cells 
were stained with OKT3 (anti-CD3), anti-CD8a, 
or an HLA-B*3501HPVG multimer at 4°C. Data 
for the untransfected parental line was left 
out of the histogram for simplicity. (c) The 
TCR-transduced JurkatCD8 cells were also 
stained at 37°C for 4 h with the HLA-
B*3501HPVG pentamer using a range of multi-
mer concentrations (final concentration 
indicated on the x axis). Mean fluorescence 
intensity (MFI) of HLA-B*3501HPVG pentamer 
staining is shown on the y axis. (d) Activa-
tion of the TCR-transduced JurkatCD8 cells  
with various concentrations of the HLA-
B*3501HPVG pentamer. CD69 up-regulation 
was used as a marker for cell activation. The  
binding of HLA-B*3501HPVG pentamer was 
performed at 37°C for 4 h. The cells were then washed and costained with APC-labeled anti-CD69 antibody for 30 min on ice. The experiments were  
conducted at least twice with similar results.
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a conserved amino-acid substitution at position 5 (HPVG-
DADYFEY; Wang et al., 2002; Zhang et al., 2004), and this 
variant was also found in six out of six viral strains from Papua 
New Guinea (unpublished data). Furthermore, the Ag876 
strain of EBV, which represents the prototype type-2 EBV 
strain, encodes another variant of this epitope, HPVAEADYFEY 
(Dolan et al., 2006). A third variant, HPVGQADYFEY, has 
also been described in type-1 EBV isolates (Snudden et al., 
1995; Bell et al., 2008).
The SKW3-TK3WT cell line recognized the HPVGEADY-
FEY and HPVAEADYFEY peptides very efficiently, whereas 
suboptimal recognition was observed for the HPVGQA-
DYFEY variant. The HPVGDADYFEY variant failed to 
stimulate significant CD69 up-regulation at any peptide con-
centration (Fig. 2 b). As mentioned in the previous section, 
the SKW3-TK3Gln55His cells were weakly responsive to the 
HPVGEADYFEY peptide, and the amino-acid substitutions 
at positions 4 or 5 resulted in further loss of stimulatory capacity 
(Fig. 2 c). The SKW3-TK3Gln55Ala cell line showed similar 
specificity for the peptide variants as the SKW3-TK3WT cell 
line (Fig. 2 d).
The TK3 CTL clone was raised from a healthy HLA-
B*3501+, EBV-sero+ Caucasian individual (Miles et al., 
2006). This primary CTL clone was next used in peptide dose–
response cytotoxicity assays, using HLA-B*3501+ PHA blasts 
as target cells, to examine whether it could recognize the 
peptide variants. Although the HPVAEADYFEY peptide 
was recognized very well by the TK3 CTLs, the two mutations 
at position 5 in the EBV epitope led to a significant reduction 
in CTL lysis at limiting peptide concentrations (Fig. 2 e).
These data demonstrate that the public TCR expressed 
by the TK3 CTL clone was finely tuned for specific recogni-
tion of the HPVGEADYFEY epitope, although it is equally 
effective at recognizing the HPVAEADYFEY sequence en-
coded by type-2 strains of EBV. Furthermore, the data estab-
lish that selection of the TRBV9*01 allele over the TRBV9*02 
allele for this public EBV-specific TCR ensures efficient rec-
ognition of the stimulating viral epitope and a greater capac-
ity to tolerate mutations in the viral epitope.
Affinity measurements
To better understand the basis for the differential recognition 
of HLA-B*3501HPVG and the HPVG variants by the TK3WT, 
TK3Gln55His, and TK3Gln55Ala TCRs, surface plasmon reso-
nance (SPR) studies were undertaken. The TK3WT TCR 
and its two variants were expressed, refolded, and purified, 
and the yields of refolded protein were equivalent for each 
TCR. Further, the TK3WT, TK3Gln55His, and TK3Gln55Ala 
TCRs appeared structurally intact in that they reacted with a 
conformationally specific anti-TCR mAb. By SPR analysis, 
the affinity (Kd) of the TK3WT TCR for HLA-B*3501HPVG 
was determined to be 2.2 µM, whereas the affinity of the 
TK3Gln55His and TK3Gln55Ala TCRs for HLA-B*3501HPVG was 
34.7 and 5.8 µM, respectively (Table II and Fig. 3). Interest-
ingly, the TK3WT TCR–HLA-B*3501HPVG interaction had a 
ninefold slower off rate (0.085 ± 0.003 s1) when compared 
Antigen-specific activation of the Jurkat transformants 
was then assayed by measuring up-regulation of cell-surface 
CD69 after incubation with varying concentrations of the 
HLA-B*3501HPVG multimer. Although the JurkatCD8-TK3WT 
and JurkatCD8-TK3Gln55Ala cell lines were activated by the 
multimer, the JurkatCD8-TK3Gln55His cells failed to show 
significant CD69 up-regulation after exposure to the pMHC 
complex (Fig. 1 d).
The JurkatCD8-TK3WT, JurkatCD8-TK3Gln55His, and 
JurkatCD8-TK3Gln55Ala cell lines were compared in dose– 
response CD69 up-regulation experiments using synthetic 
HPVGEADYFEY peptide presented on the HLA-deficient 
C1R cell line that had been transfected to express HLA-B*3501. 
In contrast to data shown in Fig. 1 d for the HLA-B*3501HPVG 
multimer, no significant differences in CD69 up-regulation 
were observed between the different cell lines after peptide 
stimulation (not depicted). We reasoned that the high levels 
of CD8 expression on the JurkatCD8 cells could mask TCR–
pMHC affinity differences, and therefore the SKW3 thymoma 
cell line, which is TCR  and  deficient and lacks high levels 
of CD8 expression (Hundhausen et al., 1992), was also trans-
duced to express either the TK3WT, TK3Gln55His, or TK3Gln55Ala 
TCRs. When these cell lines were tested in CD69 up- 
regulation experiments using various concentrations of the 
HPVGEADYFEY peptide presented on C1R–HLA-B*3501 
APCs, the SKW3-TK3Gln55His cell line was found to require 
much higher peptide concentrations for equivalent CD69 
up-regulation in comparison to the SKW3-TK3WT and SKW3-
TK3Gln55Ala cell lines (Fig. 2 a). Collectively, these results estab-
lish that the TK3WT TCR can recognize the HLA-B*3501HPVG 
complex more efficiently than the allelic variant TK3Gln55His.
HPVG sequence variants
Given the sensitivity of the TK3 TCR to micropolymor-
phism within the TRBV9 gene, we next evaluated the im-
pact of naturally occurring mutations in the HPVG epitope 
on recognition by the TK3WT, TK3Gln55His, and TK3Gln55Ala 
TCRs. The dominant EBV strains infecting Caucasians encode 
the HPVGEADYFEY sequence, as demonstrated by a recent 
study that found that 42 out of 43 Australian Caucasians 
carried strains encoding this epitope (Bell et al., 2008). In 
contrast, the dominant strain in Chinese individuals includes 
Table I. Expression of TRBV9 alleles in T cells  
from HLA-B*3501+, EBV-sero+, TRBV9*01–TRBV9*02 
heterozygous individuals
Donor HLA-B*3501HPVG  
multimer–sorted cells
Unsorted PBMCs
TRBV9*01 TRBV9*02 TRBV9*01 TRBV9*02
Donor 7 31/31 0/31 16/26 10/26
Donor 18 31/31 0/31 24/27 3/27
Donor 23 31/31 0/31 20/29 9/29
Donor 26 32/32 0/32 25/31 6/31
Donor 27 36/36 0/36 19/29 10/29
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and the structural basis for the observa-
tions described in the previous section, we 
purified the TK3 TCR–HLA-B*3501HPVG 
complex, and solved the structure at 2-Å 
resolution to an Rfac and Rfree of 22.5 and 
28.6%, respectively (Table S1). The initial 
experimental phases clearly showed unbi-
ased electron density for the HPVG peptide 
(unpublished data), and moreover, the 
electron density at the TK3 TCR–HLA-B*3501HPVG inter-
face was unambiguous. The TK3 TCR docked at 66° 
across the long axis of the HLA-B*3501HPVG complex 
(Fig. 4, a and d) and thus falls within the range of roughly 
conserved docking orientations previously observed in 
TCR–pMHC complexes (Rudolph et al., 2006). More-
over, the TK3 TCR interacted with positions 65, 69, 
and 155 of HLA-B*3501, which is consistent with the obser-
vation that TCRs invariably interact with these three 
positions on pMHC-I (Tynan et al., 2005b; Rudolph 
et al., 2006). The TK3 TCR docked centrally on the HLA-
B*3501HPVG complex, in which the total buried surface area 
(BSA) at the interface was 2,050 Å2, with 172 van der 
Waals (vdw) interactions, 18 H bonds, and 3 salt bridges 
(Tables S2 and S3).
The V and V domains contributed roughly equally to 
the BSA at the TK3 TCR–HLA-B*3501HPVG interface (55 and 
45%, respectively; Fig. 4, a and d). All six CDR loops of the 
TK3 TCR contributed to interacting with HLA-B*3501HPVG, 
albeit to varying degrees, and notably, a large number of 
framework-derived residues (12% BSA) participated in this in-
teraction. Namely, residues within the framework region of 
the TK3 TCR contacted the peptide (see following section), 
and Arg66 contacted residues Thr69, Gln72, and Thr73 on 
the 1 helix of HLA-B*3501 (Fig. 5 a and Table S2). Notably, 
Arg66 is unique to TRBV9 in that it is not found in any other 
TRBV genes. The CDR1 and CDR2 loops of the TK3 
TCR contributed 17 and 5% to the BSA, respectively, and 
with that of the TK3Gln55His TCR–HLA-B*3501HPVG inter-
action (0.787 ± 0.137 s1; Table II and Fig. 3).
We next used SPR to investigate the impact of the se-
quence variation within the HPVG epitope on recognition by 
the TK3, TK3Gln55His, and TK3Gln55Ala TCRs. Although the 
TK3WT TCR bound the HLA-B*3501HPVAEADYFEY variant 
with an affinity (4.8 µM) comparable to the cognate HLA-
B*3501HPVGEADYFEY epitope, its interaction with the HLA-
B*3501HPVGQADYFEY and HLA-B*3501HPVGDADYFEY variants 
was diminished (52 and 189 µM, respectively; Table II and 
Fig. S1). Although the TK3Gln55Ala TCR recognized the three 
peptide variants with comparable affinity to that of the TK3WT 
TCR, the TK3Gln55His TCR recognized the three peptide vari-
ants with much lower affinity (75 µM for the HPVAEADYFEY 
variant, and >200 µM for the HPVGDADYFEY and 
HPVGQADYFEY variants; Table II and Fig. S1).
Thus, consistent with the earlier functional data, the TK3WT 
TCR interacted with the HLA-B*3501–restricted HPVG epi-
tope and its variants with a higher affinity when compared with 
the TK3Gln55His TCR. This difference in affinity was primarily 
related to a much slower off rate for the wild-type TCR.
Overview of TK3 TCR–HLA-B*3501HPVG structure
Given the different affinities of the TK3 and TK3Gln55His 
TCRs toward the HLA-B*3501HPVG complex, we hypothe-
sized that these two TCRs would interact differently with 
the HLA-B*3501HPVG complex. To investigate this hypothesis 
Figure 2. T cell recognition of naturally occur-
ring variants of the HPVGEADYFEY epitope.  
(a) Activation of SKW3-TK3WT, SKW3-TK3Gln55His, and 
SKW3-TK3Gln55Ala cell lines with various concentra-
tions of the HPVGEADYFEY peptide, presented on 
C1R–HLA-B*3501 APCs. (b–d) Activation of SKW3-
TK3WT (b), SKW3-TK3Gln55His (c), and SKW3-TK3Gln55Ala 
(d) cell lines with various concentrations of the four 
variants of the HPVGEADYFEY sequence, presented 
on C1R–HLA-B*3501 APCs. Mean fluorescence inten-
sity (MFI) of CD69 was determined and plotted 
against the concentration of peptide as indicated.  
(e) The primary TK3 CTL clone was tested for  
recognition of peptides corresponding to the 
HPVGEADYFEY epitope or three variant sequences in 
dose–response cytotoxicity assays using HLA-B*3501+ 
PHA blasts as target cells. The experiments were 
conducted at least twice with similar results.
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between the CDR1 and CDR3 loops underpinned the 
restricted length of the CDR3 loop and provided a basis 
for understanding the repeated usage of the N region– 
encoded Leu109 residue. Moreover, Leu109 formed several 
specificity-governing interactions with Gln155, the main 
chain of Tyr159 and Leu163. The small side chain of N re-
gion–encoded Gly110 assisted in enabling the J-encoded 
Ser112 to form several vdw interactions with the main chain 
of Gln65, Ile66, and Thr69 and a water-mediated H bond 
with Asn70 (Fig. 5 c). The CDR1 loop did not appreciably 
contact the MHC-I, whereas the CDR2 loop interacted 
with the 1 helix of HLA-B*3501: Glu61 and Tyr57 
from the CDR2 loop contacted Gln72 and Glu76, respec-
tively (Table S2). The 108ARS110 motif and Gly111 of the 
CDR3 loop contacted the tip of the 
2 helix (residues 149–151). Namely, 
the Arg109 side chain interacted with 
Ala149, whereas its main chain inter-
acted with Ala150. Ser110 H bonded 
the main chain of Ala149 and con-
tacted Arg151, the latter of which also 
contacted Gly111, and collectively, 
the CDR1 and CDR2 loops contributed 1 and 12% to the 
BSA, respectively. The CDR3 loops collectively played the 
most prominent role, with the CDR3 and CDR3 loops 
contributing 32 and 19% of the BSA at the interface, respec-
tively, thereby providing clues toward the restricted length 
and repeated CDR3 usage.
The CDR2 loop was located peripheral to the 2 helix, 
and consequently its interactions were limited to the bulky aro-
matic ring of Tyr57 packing against the side chain of Arg151 
(unpublished data). The CDR1 loop sat above and predomi-
nantly interacted with the 2 helix, in which Arg31 inter-
digitized between Gln107 and Leu109 of the CDR3 to 
plug a cavity between the HPVG peptide and the TCR  chain, 
and H bond to Gln155 (Fig. 5 b). The unusual interplay 
Table II. Affinity measurements of the TK3, TK3Gln55His, and TK3Gln55Ala TCRs with HLA-B*3501 in complex with the HPVG peptide 
and its variants
Immobilized ligand Analyte Kd Kon Koff Kd calc
M x104/Ms 1/s M
TK3WT B*3501-HPVGEADYFEY 2.2 ± 0.2 4.01 ± 0.22 0.085 ± 0.003 2.21 ± 0.25
TK3Gln55Ala B*3501-HPVGEADYFEY 5.76 ± 0.07 1.65 ± 0.39 0.115 ± 0.004 7.345 ± 1.505
TK3Gln55His B*3501-HPVGEADYFEY 34.66 ± 1.66 3.08 ± 0.25 0.787 ± 0.137 25.6 ± 1.42
TK3WT B*3501-HPVAEADYFEY 4.8 ± 0.53 8.33 ± 2.35 0.2 ± 0.001 3.195 ± 0.115
TK3Gln55Ala B*3501-HPVAEADYFEY 12 ± 0.2 ND ND ND
TK3Gln55His B*3501-HPVAEADYFEY 74.5 ± 1.4 ND ND ND
TK3WT B*3501-HPVGDAYGFEY 189 ± 6 ND ND ND
TK3Gln55Ala B*3501-HPVGDAYGFEY 179 ± 6 ND ND ND
TK3Gln55His B*3501-HPVGDAYGFEY >200 ND ND ND
TK3WT B*3501-HPVGQAYGFEY 52.03 ± 12.83 0.151 ± 0.042 0.076 ± 0.002 54.75 ± 14.45
TK3Gln55Ala B*3501-HPVGQAYGFEY 99.6 ± 1.4 0.08 ± 0.001 0.131 ± 0.002 163.5 ± 5.5
TK3Gln55His B*3501-HPVGQAYGFEY >200 ND ND ND
Underlining indicates the variant amino acid.
Figure 3. SPR response sensograms for 
the TK3WT, TK3Gln55Ala, and TK3Gln55His TCRs. 
(a–c) A range of concentrations of the re-
folded HLA-B*3501HPVG complex was used for 
SPR response analysis with the TK3WT (a), 
TK3Gln55Ala (b), and TK3Gln55His (c) TCRs. (d) Bind-
ing curves for the three TCRs are shown, using 
graded concentrations of HLA-B*3501HPVG 
(only showing from 50 to 0 µM). The experi-
ments have been conducted in triplicate and 
the error bars are shown for each data point 
(means ± SD).
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TCR ligation, this region of the pep-
tide was stabilized, whereby the TK3 
TCR contacted the peptide substantially and contributed 42% 
BSA at the pMHC interface, a value that is at the higher end 
when compared with the TCR–pMHC database (Rudolph 
et al., 2006). Collectively, five of the CDR loops interacted 
with the HPVG peptide, contacting residues P3-Val to P8-Tyr 
and P10-Glu, forming a total of 81 vdw contacts, 13 H bonds, 
and 2 salt bridges (Table S3). P3-Val to P7-Asp were con-
tacted by the CDR1 and the CDR3 loops, in which the 
role of the CDR1 loop was restricted to Arg31 interacting 
with P4-Gly and P6-Ala. The CDR3 loop made extensive 
contact with the peptide (Fig. 5 e), with five residues of the 
HPVG peptide (P3-Val to P7-Asp) contacted by five CDR3 
residues (Leu109 and from Thr111 to Ser114; Fig. 5 e). 
Because of its small side chains, the 111TSGS114 motif (found 
exclusively in TRAJ58) was in very close proximity to the 
HPVG peptide, making a large number of contacts from 
P4-Gly to P7-Asp. The C-terminal region of the peptide, 
from P7-Asp to P10-Glu, was contacted by the three CDR 
loops (Fig. 5 f) and also by three residues of the -chain frame-
work (Tyr40, Gln55, and Arg66; Fig. 6 a). The P8-Tyr 
side chain was enveloped by the three CDR loops, in which 
the CDR1 was located above the P8-Tyr, forming contacts 
with Asp29, Leu30, and Ser31. This latter observation 
further explains TRBV9 usage, as none of the other 54 TRBV 
genes have the “DLS” motif in CDR1. In addition, the 
P8-Tyr side chain was flanked by the Tyr57 of the CDR2 
loop and the CDR3 (Ser107, Ala108, and Arg109) in 
a manner that permitted the Arg109 side chain to wrap around 
the aromatic ring of P8-Tyr (Fig. 5 f). The CDR2 loop sat 
above the P10-Glu, which formed an H bond with Tyr57 
as well as a salt bridge with the framework residue, Arg66 
(Fig. 5 f and Fig. 6 a). The P7-Asp formed vdw interactions 
these interactions underpinned the biased selection of the 
“ARS” motif (Fig. 5 d).
Having determined the structure of HLA-B*3501HPVG in 
the nonliganded state (Miles et al., 2006), we were able to 
observe the conformational changes that took place in HLA-
B*3501 upon complexation with the TK3 TCR (conforma-
tional changes within the peptide are discussed in the following 
section). Although the overall conformation of HLA-B*3501 
remained relatively rigid upon ligation (root mean square 
deviation = 0.4 Å), several HLA-B*3501 residues changed 
conformation to avoid clashes with or to form specificity-
governing contacts with the TK3 TCR. For example, the side 
chain of Arg151 flipped conformation to fit between the aro-
matic ring of Tyr57 from the CDR2 loop and Gln155 of 
HLA-B*3501 (Fig. S2 a). The latter residue also changed 
conformation as a result of Arg31 from the CDR1 loop, 
which inserted its guanadinium head group between the 2 
helix of HLA-B*3501 and the HPVG peptide. Within the 1 
helix there were five MHC residues (Asp61, Arg62, Gln65, 
Gln72, and Gln76) that changed conformation upon TK3 
TCR ligation (Fig. S2 a). For example, the Arg62 was pushed 
outside the peptide-binding groove via the CDR3 loop, 
which caused Arg62 to break its H bond with Gln65, which 
then transmitted to Gln65 forming a new interaction with 
Asp61. Accordingly, the principle role of the CDR3 loops in 
interacting with HLA-B*3501 was consistent with the biased 
CDR3 usage exhibited in this response.
Peptide-mediated contacts
In the nonliganded state, the central region (residues 5–8) of 
the HPVG peptide was highly mobile within the antigen-
binding cleft of HLA-B*3501 (Miles et al., 2006). Upon TK3 
Figure 4. Overview and footprint of the 
TK3WT, TK3Gln55His, and TK3Gln55Ala TCRs in 
complex with HLA-B*3501HPVG. (a–c) Ribbon 
representation of the TK3WT (a), TK3Gln55His (b), 
and TK3Gln55Ala (c) TCRs in complex with HLA-
B*3501HPVG. The TCR  chain is in pale pink; 
the TCR  chain is in pale blue, green, or gray 
in TK3WT, TK3Gln55His, or TK3Gln55Ala, respectively; 
HLA-B*3501 is in gray; and the HPVG peptide 
is represented as a black stick. (d–f) The foot-
prints of the TK3WT (d), TK3Gln55His (e), and 
TK3Gln55Ala (f) TCRs on the HLA-B*3501HPVG 
complex. Residues contacted by the CDR loops 
are colored in purple (CDR1), green (CDR2), 
yellow (CDR3), blue (CDR1), red (CDR2), or 
orange (CDR3) in all complexes. The interac-
tion with the framework of the TCR  chain is 
colored in pale blue. The black spheres in d, e, 
and f represent the orientation of the V and 
V chains for each TCR on the HLA-B*3501HPVG 
complex, calculated by center of mass.
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ity of the interaction when compared 
with that of the cognate interaction 
(Fig. 4, c and f; and Tables S1–S3). Both ternary complexes 
crystallized in the same space group and unit cell dimensions 
as that of the cognate complex, and thus, any structural dif-
ferences observed could be attributable to the mutation at 
TRBV9 position 55 in the TK3 TCR.
The TK3Gln55His and TK3Gln55Ala TCRs engaged HLA-
B*3501HPVG similarly to that of the TK3 TCR–HLA-
B*3501HPVG complex (overall root mean square deviation = 
0.62 and 0.92 Å, respectively; Fig. 4, b and c), burying a 
similar surface area (2,025 and 1,920 Å2 for TK3Gln55His and 
TK3Gln55Ala, respectively). However, the Gln55His mutation 
caused a decrease in the number of contacts (155 vdw con-
tacts, 15 H bonds, and 2 salt bridges) with HLA-B*3501HPVG 
when compared with the TK3 TCR–HLA-B*3501HPVG 
complex (172 vdw contacts, 18 H bonds, and 3 salt bridges), 
and the number of contacts with the TK3Gln55Ala TCR was 
decreased further (129 vdw, 13 H bonds, and 1 salt bridge; 
Tables S2 and S3). Compared with the interaction involving 
Gln55 in the cognate complex (Fig. 6 a), His55 H bonded 
to P7-Asp of the HPVG peptide in a similar manner (Fig. 6 b). 
In the TK3Gln55Ala TCR–HLA-B*3501HPVG complex, the 
interaction between position 55 and the HPVG epitope 
was lost (Fig. 6 c). Thus, the loss of contacts with HLA-
B*3501HPVG at position 55 with P7-Asp was not the sole 
discriminator for the weaker affinity of the TK3Gln55His TCR 
when compared with the TK3 TCR, as the TK3Gln55Ala TCR 
displayed a loss of contacts without decreasing the affinity 
for HLA-B*3501HPVG.
Within the TK3 TCR, the neutral Gln55 residue sat 
within a basic pocket, flanked by Arg115 and Arg66, 
and additionally surrounded by the main chain N atoms 
of R115, S114, and G113. Upon ligation with HLA-
B*3501HPVG, the negative charge of the P7-Asp residue was 
effectively neutralized by H bonding to Gln55 and salt bridg-
ing to Arg66. However, in the TK3Gln55His TCR, position 55 
with the CDR1 and CDR3 loops, an H bond with 
Ser107, and vdw contacts and an H bond with the frame-
work residue Tyr40 (Fig. 5 f). Additionally, P7-AspO2-O1 
H bonded to the polymorphic residue Gln55N2 (Fig. 6 a 
and Table S3).
As mentioned in the previous paragraph, an earlier study 
found that the central region (residues 5–8) of the HPVG 
peptide was highly mobile within the antigen-binding cleft 
of HLA-B*3501 in the nonliganded state and, therefore, the 
peptide conformation could not be modeled in its entirety 
(Miles et al., 2006). However, the bulged peptide was more 
stable when bound to HLA-B*3508, which differs from 
HLA-B*3501 at a single amino acid (position 156; Miles et al., 
2006). We were therefore able to compare the conformation 
of the central bulged region of the peptide in the HLA-
B*3508HPVG unliganded structure and in the TK3 TCR–HLA-
B*3501HPVG complex. This comparison suggested that the 
conformation of the peptide bulge was altered in the TCR-
ligated complex, allowing the TCR to maximize MHC-I 
contacts (Fig. S2 b). The TCR regions responsible for these 
changes in peptide conformation are the CDR3 loop and 
the framework residues Arg66 and Gln55. Accordingly, 
the TK3 TCR substantially contacted the HPVG epitope and 
included an interaction with the polymorphic Gln55 residue.
The structural impact of micropolymorphism  
within the TRBV9 gene
To investigate the structural impact of the sequence mi-
cropolymorphism between the TRBV9*01 and TRBV9*02 
alleles, we next determined the structure of the TK3Gln55His 
TCR–HLA-B*3501HPVG complex to 2.1-Å resolution with an 
Rfac and Rfree of 22.8 and 27.6%, respectively (Fig. 4, b and e). 
Additionally, we solved the structure of the TK3Gln55Ala 
TCR–HLA-B*3501HPVG complex to 2.7-Å resolution to 
 establish why the Gln55Ala mutation did not affect the affin-
Figure 5. TK3WT contacts with HLA-
B*3501 and with the HPVG epitope.  
(a–d) Contacts between the HLA-B*3501 mol-
ecule and the TK3WT FW (a), CDR1 and 
CDR3 (b), CDR3 (c), and CDR3 (d) are 
shown, with the HLA-B*3501 and selected 
side chains depicted in white. The CDR loops 
and selected side chains of the TCR are col-
ored as in Fig. 4 for all of the panels, and the 
peptide is represented as a pink stick. The blue 
and red dashed lines represent the vdw and 
polar interactions, respectively, and the  
red sphere represents a water molecule.  
(e and f) Interactions between the HPVG peptide 
and the TCR. (e) The interaction between the 
CDR1 and CDR3 with residues P4–P7 of 
the HPVG peptide. (f) The interaction between 
the three CDR loops with the HPVG peptide.
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the molecular basis for these functional differences was re-
vealed by structural studies showing that micropolymorphism 
within the TRBV9 gene affects stabilizing interactions be-
tween the TCR  chain and the antigenic peptide.
By examining TCR usage in the response to the HPVG 
viral epitope in donors heterozygous for two common alleles 
of the TRBV9 gene segment, we showed that TRBV9*01-
expressing T cells, but not TRBV9*02-expressing T cells, 
were selected in this highly biased T cell response. The basis 
for this observation became clear from experiments that 
showed reduced affinity and functional recognition of the 
HLA-B*3501HPVG complex when the TRBV9*02 TCR was 
used in place of the wild-type TRBV9*01 TCR. In contrast, 
an earlier study demonstrated that the TRBV9*02 allele was 
used by an HLA-A2–restricted human immunodeficiency 
virus pol-specific CTL clone, and that introducing a Gln (as 
in TRBV9*01) in place of the His residue at TRBV position 
55 resulted in loss of recognition of the viral peptide (Vessey 
et al., 1996). These contrasting observations suggest a func-
tional basis for the retention of these closely related TRBV9 
alleles in diverse human populations. Thus, selection pressure 
from various pathogens may maintain both TRBV9*01 and 
TRBV9*02 in the population because each imparts distinct 
T cell specificity characteristics that may favor recognition 
of different peptide–MHC complexes. Further, a previous 
report demonstrated that allelic polymorphism in the CDR1 
domain of a mouse V10 gene segment affected recognition 
of a foreign peptide derived from an HLA molecule (Bour 
et al., 1999), supporting the conclusion that TCR gene poly-
morphism can influence specificity and TCR selection in 
CD8+ T cell responses.
Our previous TCR repertoire analysis of the response to 
the HPVG epitope showed that TRBV9+ T cells dominated 
in four out of five HLA-B*3501+ donors, but a fifth 
donor used both TRBV9+ and TRBV28+ T cells in roughly 
equal numbers (Miles et al., 2006), establishing that TRBV9 
is not an absolute requirement for recognition of this 
HLA-B*3501HPVG complex. Although 0 out of 27 HLA-
B35+, EBV-exposed individuals recruited for the present 
study was homozygous for the TRBV9*02 allele, it is likely 
that such donors would respond to the HPVG epitope with 
TCRs encoded by V genes other than TRBV9. Thus, 
was replaced by the positively charged His residue, thereby 
creating a more electropositively charged pocket within the 
TK3 TCR. To accommodate this additional positive charge, 
the conformations of these neighboring Arg residues were subtly 
altered, resulting in the loss of a direct salt bridge between 
P7-Asp and Arg66, the loss of a direct H bond between 
Arg115 and Ser112-O, and a reduction in the vdw con-
tacts with HLA-B*3501 (Fig. 6 b and Fig. S2 c). Consequently, 
the TK3Gln55His TCR less readily accommodates the negative 
charge of the P7-Asp, which accounts for the 10 times faster 
dissociation of the TK3Gln55His–HLA B*3501HPVG complex 
when compared with both the TK3WT and TK3Gln55Ala 
TCRs in complex with the same pHLA (Table II). Accordingly, 
altered charge complementarity at the interface between the 
TK3 TCR and HLA-B*3501HPVG underpinned the weaker 
interaction and faster dissociation with the TK3Gln55His TCR, 
and the preferential selection of TRBV9*01 over TRBV9*02 
in this response.
DISCUSSION
Given the central role that T cells play in immune responses 
and immune-related disorders, polymorphism in the TCR 
genes has long been suspected as a potential candidate for disease 
susceptibility, and recent studies identifying extensive allelic 
sequence variation in the TCR V genes support this conten-
tion (Subrahmanyan et al., 2001; Mackelprang et al., 2006). 
Indeed, genomic polymorphisms of TCR genes have been 
found in association with common immune diseases such as 
multiple sclerosis (Seboun et al., 1989; Hibberd et al., 1992; 
Hockertz et al., 1998), asthma (Moffatt et al., 1994, 1997; 
Cho et al., 2001), and narcolepsy (Hallmayer et al., 2009); 
however, the mechanisms controlling these effects are not 
understood. Although these associations imply that micropoly-
morphism within the TCR genes can influence T cell recog-
nition and/or repertoire selection, our present study is the first 
to directly characterize the structural and functional impact of 
allelic sequence variation in the TCR loci. Our demonstration 
that a single amino-acid difference within a TRBV gene can 
reduce TCR binding affinity for a viral peptide–MHC com-
plex and preclude its dominant selection in an antiviral T cell 
response sheds light on how allelic polymorphism in the TCR 
loci affects the adaptive immune response. Furthermore, 
Figure 6. Interactions with the polymor-
phic TCR residue. (a–c) Interaction between 
the TK3WT (a), TK3Gln55His (b), and TK3Gln55Ala (c) 
TCRs with the peptide, localized at the poly-
morphic site of the  chain. The different 
chains are colored as in Fig. 4, the residues 
involved in the interaction are represented as 
sticks, and all of the panels show the same 
orientation of the different structures. (b) Loss 
of a direct H bond between the Arg66 and 
D7, and also between the Arg115 and the 
Ser112 in the TK3Gln55His structure when com-
pared with the TK3WT (a). The loss of contacts is greater in the TK3Gln55Ala structure (c) when compared with the TK3WT complex (a). The blue and red dashed 
lines represent the vdw and polar interactions, respectively, and the red sphere represents a water molecule.
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(Invitrogen) was used with a TRBV9 family–specific primer (5-AGTCA-
CACAAACCCCAAAGC-3) and a constant region primer (5-TTCT-
GATGGCTCAAACAC-3). The PCR products were purified and cloned 
into the pGEM-T vector system (Promega) and sequenced using the BigDye 
Terminator reaction kit. Human protocols were approved by the Queensland 
Institute of Medical Research Human Research Ethics Committee.
TCR cloning, protein expression, and purification. cDNA was re-
verse transcribed from TK3 T cell RNA using SuperScript II. PCR products 
encoding the TK3 TCR  and  chains were cloned into pGEM-T Easy 
before cotransferring into the pMIG vector (Holst et al., 2006). The primers 
were as follows (italicized nucleotides represent restriction sites and lower-
cased nucleotides represent TCR gene sequences): P1, 5-CGGAATTCGC-
TAGCCACCatggagaaaatgttggagtgt-3; P2, 5-GGGCCCTGGGTTC-
TCTTCGACGTCGCCGGCCTGCTTAAGCAGCGAGAAATTGGTG-
GCGCCGGATCCgctggaccacagccgcagcgt-3; P3, 5-GGATCCGGCGC-
CACCAATTTCTCGCTGCTTAAGCAGGCCGGCGACGTCGAAGA-
GAACCCAGGGCCCatgggctgcaggctcctctgc-3; and P4, 5-CCGCTCGA-
GCTGCAGctagcctctggaatcctttct-3.
The variant TCRs TK3Gln55His and TK3Gln55Ala were generated from 
the parental pGEM-TK3WT-2A-TK3WT plasmid DNA through site- 
directed mutagenesis. The corresponding inserts were transferred to the pMIG 
vector and the resulting constructs were denoted as pMIG-TK3WT (TK3WT-
2A-TK3WT), pMIG-TK3Gln55His (TK3WT-2A-TK3Gln55His), and pMIG-
TK3Gln55Ala (TK3WT-2A-TK3Gln55Ala). The mutagenesis primers were 
as follows (underlined nucleotides represent mutation codons): Gln55Ala 
P5, 5-CTCCAGTTCCTCATTGCGTATTATAATGGAGAAG-3; P6, 
5-CTTCTCCATTATAATACGCAATGAGGAACTGGAG-3; Gln55His 
P7, 5-CTCCAGTTCCTCATTCACTATTATAATGGAGAAG-3; and 
P8, 5-CTTCTCCATTATAATAGTGAATGAGGAACTGGAG-3.
The TK3WT, TK3Gln55His, and TK3Gln55Ala TCRs were expressed, 
refolded, and purified using an engineered disulfide linkage in the constant 
domains between the TRAC and TRBC. Both the  and  chains of the 
TK3WT TCR and the mutant versions were expressed separately as inclusion 
bodies in the BL21 E. coli strain. Inclusion bodies were resuspended in 8 M 
urea, 20 mM Tris-HCl, pH 8, 0.5 mM Na-EDTA, and 1 mM dithiothreitol. 
The TCRs were refolded by flash dilution in a solution containing 3 M urea, 
100 mM Tris, pH 8, 2 mM Na-EDTA, 400 mM l-arginine–HCl, 0.5 mM of 
oxidized glutathione, and 5 mM of reduced glutathione. The refolding solu-
tion was dialyzed to eliminate the urea. The resulting protein solution was 
purified by gel filtration and HiTrap-Q anion exchange chromatography.
Soluble class I heterodimers containing the HPVG peptide (or variant 
peptides) were prepared as described previously (Macdonald et al., 2002). In 
brief, a truncated form (amino-acid residues 1–276) of the HLA-B*3501 
heavy chain and full-length 2-microglobulin (2m) were expressed in 
E. coli as inclusion bodies. Each HLA-B*3501–peptide complex was refolded 
by diluting the heavy chain and 2m inclusion body preparations into refold-
ing buffer containing a molar excess of peptide ligand. The refolded com-
plexes were concentrated and purified by anion exchange chromatography. 
The complexes were further purified by gel filtration and HiTrap-Q anion 
exchange chromatography.
Retroviral transduction into JurkatCD8 and SKW3 cells. JurkatCD8 cells 
were generated previously, and they lack a TCR  chain (TCR+; Beddoe 
et al., 2009). SKW3 cells are TCR (double deficient), and they were pur-
chased from the German Collection of Microorganisms and Cell Cultures.
JurkatCD8–TK3WT, JurkatCD8–TK3Gln55Ala, and JurkatCD8–TK3Gln55His 
cell lines were created via retroviral transduction as described previously (Holst 
et al., 2006; Beddoe et al., 2009). In brief, the plasmids pMIG-TK3WT, pMIG-
TK3Gln55Ala, or pMIG-TK3Gln55His (4 µg) were individually combined with the 
packaging vectors pPAM-E (4 µg) and pVSV-g (2 µg) and cotransfected into 
106 293T cells in a 10-cm dish with FuGENE 6 (Roche) as previously 
described (Holst et al., 2006). The transiently transfected 293T cells were fur-
ther cultured for 5 d. During this time, the retrovirus-containing supernatant 
was collected twice daily and used to transduce JurkatCD8 cells along with 
retention of the TRBV9*02 allele in the population may 
increase the overall TCR repertoire diversity against this epi-
tope, thereby protecting the population against viral epitope 
variants that escape recognition by the dominant public TCR. 
The HPVGDADYFEY epitope variant, for example, which 
is found in EBV strains infecting Chinese individuals, was 
recognized suboptimally by the public TRBV9*01+ TK3 TCR 
and particularly poorly by the TK3Gln55His TCR, and there-
fore, alternative TCRs are likely to be recruited in the response 
to this peptide.
A study of polymorphism within the human TRBV gene 
segments showed that nonsynonymous variants are evenly 
distributed between the framework and CDR regions (50 in 
framework regions and 8 in CDR regions), and it was suggested 
that the SNPs mapped to the CDR regions may alter the avidity 
or specificity of the TCR (Subrahmanyan et al., 2001). Our data 
demonstrate that coding polymorphisms within framework resi-
dues are also functionally relevant, directly affecting TCR affin-
ity toward HLA-B*3501HPVG, thereby raising the possibility that 
coding polymorphisms anywhere along the TRBV gene could 
potentially influence immune function.
Recently, structural studies have suggested that the germline-
encoded regions of a TCR dictate MHC bias (Feng et al., 
2007; Dai et al., 2008; Scott-Browne et al., 2009). However, 
we show in this study that the germline-encoded polymorphic 
residue within TRBV9 exclusively contacted the viral epitope, 
and this interaction effectively determined the functional out-
come of this MHC-restricted response.
This study has highlighted the structural and functional 
relevance of nonsynonymous TCR V gene polymorphism, 
suggesting that it may have evolved to further diversify the 
immune repertoire. Given the structural and functional im-
pact of the TRBV gene polymorphism documented in this 
paper, it will be important to examine the complementary 
role of TCR polymorphism and MHC associations in auto-
immune disease involving well-defined self-antigens. Our 
data provide insights into the mechanisms controlling dis-
ease associations with allelic sequence variation in the TCR 
loci, and suggest its potentially important role in shaping the 
antiviral T cell repertoire, thereby contributing toward inter-
individual variability in T cell responses and the outcome 
of infection.
MATERIALS AND METHODS
TCR sequencing. The CTL clones TK3, MW1, and CS1 have been char-
acterized previously, and TCR  and  chain sequences were determined as 
previously described (Miles et al., 2006). For TRBV9 genotyping, genomic 
DNA samples were obtained from PBMCs from 27 healthy, HLA-B*35+ 
EBV-exposed Caucasian individuals. The polymorphic region of the TRBV9 
gene segment was amplified by PCR using the primers 5-TTCAG-
GCTCCTCTGCTGTGT-3 and 5-GTGGGGCAGGAATGTTATTG-3. 
The PCR products were purified using the MinElute PCR Purification Kit 
(QIAGEN) and directly sequenced in both directions using the BigDye 
Terminator reaction kit (Applied Biosystems).
To examine TRBV9*01 versus TRBV9*02 expression in the T cell 
repertoire, total RNA was extracted using TRIzol reagent from PBMCs or 
HLA-B*3501HPVG–specific T cells isolated by FACS after staining with a 
pMHC pentamer (ProImmune). A one-step SuperScript II PCR reaction kit 
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PEG 3350, 0.2 M Li2SO4, and 0.1 M Na-citrate, pH 5.6. The crystals of 
TK3Gln55His and TK3Gln55Ala in complex with HLA-B*3501HPVG were ob-
tained in the same conditions.
Data collection and structure determination. The TCR–pMHC 
crystals were soaked in a cryoprotectant solution containing mother liquor solu-
tion with a PEG concentration increased to 30% (wt/vol), and were flash frozen 
in liquid nitrogen. The data were collected on the 3BM1 beamline at the Aus-
tralian Synchrotron, Clayton using a charge-coupled device detector at 100 K 
(Quantum 210; Area Detector Systems Corporation). Data were processed using 
XDS software and scaled using XSCALE software (Kabsch, 1993).
The TK3–HLA-B*3501HPVG crystal (and the other complexes) 
belonged to the space group P1 (Table S1), with unit cell dimensions consis-
tent with one complex in the asymmetric unit. The structure was deter-
mined by molecular replacement using the PHASER program (Read, 2001) 
with the CF34 TCR as the search model for the TCR (PDB accession no. 
3FFC; Gras et al., 2009) and the HLA-B*3501HPVG complex for the MHC 
model without the peptide (PDB accession no. 2FYY; Miles et al., 2006). 
Manual model building was conducted using COOT software (Emsley and 
Cowtan, 2004), followed by maximum-likelihood refinement with the 
REFMAC 5 program (CCP4 suite; Collaborative Computational Project, 
Number 4, 1994; Murshudov et al., 1997). Translation, liberation, and 
screw-rotation displacement refinement was also used during the refinement 
process to model anisotropic displacements of defined domains. The TCR 
was numbered according to the ImMunoGeneTics unique numbering 
system (Lefranc, 2003), whereby the CDR1 loops start at residue 27, the 
CDR2 loops start at residue 56, and the CDR3 loops start at residue 105. 
The final model was validated using the PDB validation web site and the 
final refinement statistics are summarized in Table S1. All molecular graphics 
representations were created using PyMOL (DeLano, 2002).
PDB accession numbers. The coordinates of the TK3WT–HLA-B*3501HPVG, 
TK3Gln55His–HLA-B*3501HPVG, and TK3Gln55Ala–HLA-B*3501HPVG com-
plexes have been deposited under PDB accession nos. 3MV7, 3MV8, and 
3MV9, respectively.
Online supplemental material. Table S1 summarizes data collection and 
refinement statistics for the structural studies. Table S2 lists the TCR–MHC 
contacts in the three TCR–pMHC complexes. Table S3 lists the TCR– 
peptide contacts in the three TCR–pMHC complexes. Fig. S1 shows SPR 
data for the TK3WT, TK3Gln55His, and TK3Gln55Ala TCRs with HLA-B*3501 
bound to HPVG and its natural variants. Fig. S2 shows conformational 
changes in the pMHC upon ligation with TK3WT, and structural differences 
between the TK3WT–HLA-B*3501HPVG and TK3Gln55His–HLA-B*3501HPVG 
complexes. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20100603/DC1.
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